We are live on ! Find out more
KYMR icon

Kymera Therapeutics

100 hedge funds and large institutions have $972M invested in Kymera Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 30 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 30

7.17% more ownership

Funds ownership: 88.38%95.55% (+7.2%)

21% less funds holding

Funds holding: 126100 (-26)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

50% less capital invested

Capital invested by funds: $1.93B → $972M (-$961M)

66% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 35

Holders
100
Holders Change
-26
Holders Change %
-20.63%
% of All Funds
1.68%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
12
Increased
42
Reduced
30
Closed
35
Calls
$3.32M
Puts
Net Calls
+$3.32M
Net Calls Change
-$4.68M
Name Holding Trade Value Shares
Change
Change in
Stake
Teacher Retirement System of Texas
126
Teacher Retirement System of Texas
Texas
-$244K -5,755 Closed
Janus Henderson Group
127
Janus Henderson Group
United Kingdom
-$236K -5,588 Closed
BCM
128
Bayesian Capital Management
New York
-$202K -4,780 Closed
LSA
129
Leonteq Securities AG
Switzerland
-$105K -2,477 Closed
QT
130
Quantbot Technologies
New York
-$63K -1,500 Closed
PHK
131
Point72 Hong Kong
Hong Kong
-$53K -1,263 Closed
US Bancorp
132
US Bancorp
Minnesota
-$9K -204 Closed
PFS
133
Prospera Financial Services
Texas
-$6K -136 Closed
Group One Trading
134
Group One Trading
Illinois
-$2.08K -89 Closed
LC
135
Lindbrook Capital
California
+$280 +12 New

KYMR Hedge Fund Activity: Q2 2022 in Review

100 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2022, worth a combined $972M — down 50% from $1.93B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of KYMR and 12 opened new positions — a net loss of 23 holders — while 30 trimmed existing stakes and 42 added.

The largest buyer was Wellington Management Group, adding an estimated $42.3M. The largest seller was Fidelity Investments, cutting an estimated $36.8M.

  • 100 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2022, down from 126 in Q1 2022.
  • Funds reported $972M of Kymera Therapeutics stock for Q2 2022, down 50% quarter-over-quarter.
  • 12 funds opened new Kymera Therapeutics positions in Q2 2022 and 35 closed out, a net change of -23 holders.
  • The largest Kymera Therapeutics buyer in Q2 2022 was Wellington Management Group, an estimated $42.3M added.
  • The largest Kymera Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $36.8M sold.

Based on aggregated 13F filings for Q2 2022.